Andere talen Neurotech International Limited

Aandelen

NTI

AU000000NTI9

Beurs gesloten - Australian S.E. Andere beurzen 08:10:42 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,091 ^AUD	0,00%		-1,09%	+31,88%

10/04	Neurotech International beëindigt Fase II/III NTIASD2 klinische studie voor kinderen met autisme	MT
26/02	Neurotech International Limited rapporteert resultaten voor het halfjaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	17/04
Neurotech International Completes AU$10 Million Capital Raise	17/04
Rice Biotech Launch Pad startup Motif Neurotech announces peer-reviewed publication on wireless cortical stimulator for precise neuromodulation	15/04
Neurotech International Concludes Phase II/III NTIASD2 Trial for Children with Autism	10/04
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2023	26/02
Neurotech Receives Human Research Ethics Committee Approval to Extend Autism Trial	13/02
Neurotech's ASD Drug Trials Exceed 90 Weeks	07/02
Neurotech International Secures Approval to Advance Cerebral Palsy Trial; Shares Rise 6%	29/01
Neurotech International Completes Enrolment for Phase 2/3 Autism Spectrum Trial	19/12
Neurotech International Secures Ethics Approval for Use of Autism Spectrum Medication in Adults	04/12
Neurotech International Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023	14/11
Retinitis Pigmentosa Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	13/11
Butterfly Network Announces 5-Year Co-Development Agreement with Forest Neurotech for Next-generation Brain Computer Interfaces Using Ultrasound-on-Chip Technology	25-10-23
Neurotech International Completes Enrollment for Rett Syndrome Trial	26-09-23
Alex Gorsky Joins Neurotech's Board as Lead Director	14-09-23
Neurotech International Completes Treatment for Last Patient in Phase I/II PANDAS/PANS Clinical Trial	31-08-23
Neurotech International Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30-08-23
Neurotech International Secures Ethics Approval for Clinical Trial of Neurological Medication	10-07-23
Neurotech International Secures Ethics Approval to Extend Use of Medication in Pediatric Trial	30-05-23
Neurotech International Completes Patient Recruitment for Neuropsychiatric Disorder Treatment Trial	03-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Neurotech International Limited

Aandelen

NTI

AU000000NTI9

Andere talen

Filters